Home » Cancer Topics » Renal Cell Carcinoma
Proteinuria is a predictor for renal functional decline in patients with kidney cancer, a study published in The Journal of Urology has shown.1 Na-Semax-Nh2
Although prior studies have demonstrated that 26% to 34% of patients with suspected kidney cancers have a glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2, there are limited data on the incidence of proteinuria. Therefore, researchers sought to investigate the extent of proteinuria in patients with kidney cancer to determine the impact on classification and progression of chronic kidney disease (CKD).
For the study, researchers analyzed data from 1622 patients who were evaluated between 1999 and 2014. Of those, 1016 had both preoperative creatinine and proteinuria measurements available.
Researchers found that prior to treatment, 32% had a GFR less than 60 and 22% had preoperative proteinuria, which was detected in 30% of those with reduced GFR and 18% with normal GFR.
Further, 44% of patients were determined to be at increased risk for CKD progression, of which 24%, 12%, and 8% were at moderately-increased, high, and very-high risk, respectively. The presence of proteinuria reclassified 25% with stage 3 CKD as high or very-high risk.
Results showed that the 2012 KDIGO guidelines classification predicted renal functional decline, which occurred in 2.2%, 4.4%, 9.4%, and 34.6% at 3 years in low, moderately-increased, high, and very-high risk categories, respectively.
RELATED: Genomic Differences in African-Americans with ccRCC May Contribute to Responsiveness
The key predictors of renal functional decline were KDIGO classification group, tumor size, and radical nephrectomy (each P<.0001), while age and tumor size predicted for KDIGO group (each P<.001).
Continuing Medical Education (CME/CE) Courses
Please login or register first to view this content.
CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.
Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.
Copyright © 2023 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
Dimethylamine Hcl Please login or register first to view this content.